Wall Street Analysts Predict a 27.09% Upside in Adma Biologics (ADMA): Here's What You Should Know

Shares of Adma Biologics (ADMA) have gained 21.6% over the past four weeks to close the last trading session at $5.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $6.38 indicates a potential upside of 27.1%.The mean estimate comprises four short-term price targets with a standard deviation of $0.48. While the lowest estimate of $6 indicates a 19.5% increase from the current ...